The 5-year OS rate was 29.6% for treatment-naive patients with PD-L1-high (tumor proportion score [TPS] ≥ 50%) NSCLC and 15.7% for treatment-naive patients with PD-L1-low (TPS 1%–49%) NSCLC (70). This evidence concerns the gene CD274 and non-small cell lung carcinoma.